Company Encyclopedia
View More
name
Protalix Biotherap
PLX.US
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A.
1.946 T
PLX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
BiotechnologyIndustry
Industry Ranking45/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE12.64%B
    • Profit Margin8.72%B
    • Gross Margin53.37%B
  • Growth ScoreA
    • Revenue YoY35.42%A
    • Net Profit YoY156.15%A
    • Total Assets YoY33.63%A
    • Net Assets YoY63.11%A
  • Cash ScoreB
    • Cash Flow Margin1146.46%B
    • OCF YoY35.42%A
  • Operating ScoreB
    • Turnover0.86B
  • Debt ScoreB
    • Gearing Ratio35.69%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Protalix BioTherapeutics showcases pipeline advances and growth strategy for rare disease treatments

    Protalix BioTherapeutics Inc. reported $53 million revenue for 2024 and $25.4 million for the first half of 2025. With $33.4 million cash and no debt, it aims for positive cash flow by 2027. The company focuses on enzyme therapies for Fabry and Gaucher diseases, and plans Phase 2 trials for PRX-115 for gout. Key milestones include market expansion and geographic approvals.

    Reuters·
    US
    PLX
    +1.74%
    Reuters·
    US
    PLX
    +1.74%

    Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2025 Earnings Call Transcript

    Protalix BioTherapeutics, Inc. (AMEX:PLX) reported its Q3 2025 earnings, missing expectations with an EPS of $0.02914 compared to the expected $0.06.

    MSN·
    US
    PLX
    +1.74%
    MSN·
    US
    PLX
    +1.74%

    Protalix Biotherap | 10-Q: FY2025 Q3 Revenue Misses Estimate at USD 17.85 M

    LB filings·
    US
    PLX
    +1.74%
    LB filings·
    US
    PLX
    +1.74%

    Protalix Biotherap | 8-K: FY2025 Q3 Revenue Misses Estimate at USD 17.85 M

    LB filings·
    US
    PLX
    +1.74%
    LB filings·
    US
    PLX
    +1.74%

    Celcuity Q3 Adjusted EPS USD -0.78 Vs. IBES Estimate USD -1.02

    Nov 12 (Reuters) - Celcuity Q3 net income USD -43.8 million. * Q3 adjusted net income USD -37.2 million vs. IBES estimate USD -43 million * Q3 operating expenses USD 42.8 million * Q3 EPS USD -0.92

    Reuters·
    US
    CELC
    +5.87%
    Reuters·
    US
    CELC
    +5.87%
    © 2025 Longbridge｜Disclaimer